만성 C형 간염의 신이식 환자에서 페그인터페론 알파와 리바비린병합치료로 치유한 1예
Chronic hepatitis C healed by peginterferon-α and rivabirin treatment after kidney transplantation
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Hepatitis C virus (HCV) infection is present in a high proportion of patients with kidney transplantation. Compared with uninfected kidney transplant recipients, HCV infected kidney recipient have higher prevalence of liver disease and worse allograft survival after transplantation. Interferon monotherapy before transplantation is standard therapy for HCV-infected kidney transplant candidates. If HCV infection is discovered after transplantation, interferon monotherapy is considered due to the limited critical situation. However, in this patient, who was a kidney recipient, HCV infection was treated after kidney transplantation with peginterferon-α and rivabirin. As a result, the patient achieved sustained virologic response.
Abstract
Hepatitis C virus (HCV) infection is present in a high proportion of patients with kidney transplantation. Compared with uninfected kidney transplant recipients, HCV infected kidney recipient have higher prevalence of liver disease and worse allograft survival after transplantation. Interferon monotherapy before transplantation is standard therapy for HCV-infected kidney transplant candidates. If HCV infection is discovered after transplantation, interferon monotherapy is considered due to the limited critical situation. However, in this patient, who was a kidney recipient, HCV infection was treated after kidney transplantation with peginterferon-α and rivabirin. As a result, the patient achieved sustained virologic response.
참고문헌 (19)
- Pereira BJ, "Hepatitis C virus infection in dialysis and renal transplantation", Kidney Int, 51, pp.981~999 (1997)
- Aroldi A, "Renal transplant recipients and chronic liver disease: statistical evaluation of predisposing factors", Nephron, 61, pp.290~292 (1992)
- Fabrizi F, "Hepatitis C virus infection and renal transplantation", Am J Kidney Dis, 38, pp.919~934 (2001)
- Fishman JA, "Hepatitis C virus and organ transplantation", Transplantation, 62, pp.147~154 (1996)
- Kim DY, "A nationwide seroepidemiology of hepatitis C virus infection in South Korea", Liver Int, 33, pp.586~594 (2013)
- Kim H, "Prevalence and risk factors of hepatitis C virus infection in chronic hamodialysis patients (multi-center study)", Korean J Med, 52, pp.833~840 (1997)
- Shin YH, "Prevalence of anti-HCV in hemodialysis patients in Taegu and Kyeongbuk, Korea", Korean J Med, 54, pp.640~646 (1998)
- Bang BK, "Prevalence and clinical course of hepatitis B and hepatitis C liver disease in ciclosporin-treated renal allograft recipients", Nephron, 70, pp.397~401 (1995)
- Huang CC, "The clinical outcome of hepatitis C virus antibody-positive renal allograft recipients", Transplantation, 53, pp.763~765 (1992)
- Periera BJ, "The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation", Transplantation, 60, pp.799~805 (1995)
- Lee HJ., "Effect of α-interferon treatment on serum ALT levels in patients with chronic hepatitis C", Yeungnam Univ J Med, 10, pp.190~196 (1993)
- Kamar N, "Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology", Am J Kidney Dis, 42, pp.184~192 (2003)
- Wéclawiack H, "Alpha-interferon therapy for chronic hepatitis C may induce acute allograft rejection in kidney transplant patients with failed allografts", Nephrol Dial Transplant, 23, pp.1043~1047 (2008)
- Harihara Y, "Interferon therapy in renal allograft recipients with chronic hepatitis C", Transplant Proc, 26, pp.2075~ (1994)
- "KDIGO clinical practice guidelines for the preventation, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease", Kidney Int, 73(Suppl 109), pp.S53~S68 (2008)
- Pereira BJ, "Transmission of hepatitis C virus by organ transplantation", N Engl J Med, 325, pp.454~460 (1991)
- Chan TM, "Prevalence of hepatitis C virus infection in hemodialysis patients: a longitudinal study comparing the results of RNA and antibody assays", Hepatology, 17, pp.5~8 (1993)
- "KDIGO clinical practice guidelines for the preventation, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease", Kidney Int, 73(Suppl 109), pp.S20~S45 (2008)
- Ning Q, "Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response", J Immunol, 160, pp.3487~3493 (1998)